ContextVision (CONTX)

[TekBot]

ContextVision - Company presentation held at SpareBank 1 Markets Webinar

Stockholm, June 12(th), 2020 - Today ContextVision presented the company at a
webinar arranged by SpareBank 1 Markets in Norway.

…

Vis børsmeldingen

CEO Fredrik Palm gave an update of the company’s development and shared the
company’s future direction. Please find a PDF-version of the presentation
attached. The presentation will also be published on the company’s website.

For further information, please contact ContextVision’s CEO, Fredrik Palm, at
+46 76 870 25 43 or visit www.contextvision.com.

                                  ###

About ContextVision

ContextVision is a medical technology software company that specializes in image
analysis and artificial intelligence. As the global market leader within image
enhancement, ContextVision is a software partner to leading medical imaging
manufacturers around the world. Its cutting-edge technology helps doctors
accurately interpret medical images, a crucial foundation for better diagnosis
and treatment.

As an industry pioneer for more than 30 years, ContextVision has developed
state-of-the-art capabilities in the latest artificial intelligence
technologies. By combining these with its well-established GOP technology, the
company is introducing a new generation of image enhancement products.
ContextVision are determined to expand by approaching the growing digital
pathology market with new AI-based decision support tools for pathologists.

The company is based in Sweden, with local representation in the U.S., Russia,
Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under
the ticker COV.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act

Kilde

[TekBot]

ContextVision - Company presentation held at SpareBank 1 Markets Webinar

Stockholm, June 12(th), 2020 - Today ContextVision presented the company at a
webinar arranged by SpareBank 1 Markets in Norway.

…

Vis børsmeldingen

CEO Fredrik Palm gave an update of the company’s development and shared the
company’s future direction. Please find a PDF-version of the presentation
attached. The presentation will also be published on the company’s website.

For further information, please contact ContextVision’s CEO, Fredrik Palm, at
+46 76 870 25 43 or visit www.contextvision.com.

                                  ###

About ContextVision

ContextVision is a medical technology software company that specializes in image
analysis and artificial intelligence. As the global market leader within image
enhancement, ContextVision is a software partner to leading medical imaging
manufacturers around the world. Its cutting-edge technology helps doctors
accurately interpret medical images, a crucial foundation for better diagnosis
and treatment.

As an industry pioneer for more than 30 years, ContextVision has developed
state-of-the-art capabilities in the latest artificial intelligence
technologies. By combining these with its well-established GOP technology, the
company is introducing a new generation of image enhancement products.
ContextVision are determined to expand by approaching the growing digital
pathology market with new AI-based decision support tools for pathologists.

The company is based in Sweden, with local representation in the U.S., Russia,
Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under
the ticker COV.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act

Kilde

[Hypergris]

https://newsweb.oslobors.no/obsvc/attachment.obsvc?messageId=507849&attachmentId=201709&obsvc.item=1

[TekBot]

ContextVision - Invitation to Extraordinary General Meeting 2020

STOCKHOLM - June 24, 2020 - ContextVision hereby invites shareholders to an
Extraordinary General Meeting on August 5, 2020. Please find attached the
invitation including agenda and details on how to register. Please contact:
…

Vis børsmeldingen

[email protected] for any questions regarding the Extraordinary
General Meeting.

For inquiries, please contact CFO Ann-Charlotte Linderoth
E-mail: [email protected]

                                  ###

About ContextVision
ContextVision is a medical technology software company specialized in image
analysis and artificial intelligence. As the global market leader within image
enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-
ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary
technology and artificial intelligence for image-based applications. Our
cutting-edge technology helps clinicians accurately interpret medical images, a
crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are
re-investing significantly in our product portfolio of decision support tools
and we are dedicated to becoming a leading resource for pathologists to
radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation
in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock
Exchange under the ticker COV.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act

Kilde

[Brutal]

DECISION ON A SHARE SPLIT OF THE COMPANY’S SHARE(PARAGRAPH7)
The Board of Directors proposes that the Extraordinary General Meeting,in order to achieve a number of shares suitable for the Company, decide to increase the number of shares in the Company by dividing each share into 10 shares (share split 10:1). After the split of shares, the number of shares in the Company will increase from 7,736,750 to 77,367,500.
The proposed share split means that the share’s quota value will change from SEK 0.2694 to SEK 0.0269

Utelukkende positivt!? Mere likvid aksje - større freefloat og lettere for større institusjoner å komme inn.

https://www.personligfinans.no/2019/10/16/aksjesplitt-og-aksjepleis/ - hvis du ønsker å lese mere.

[TekBot]

ContextVision announces first CE marked digital pathology product

STOCKHOLM - June 29, 2020 - ContextVision, a medical technology software company
specializing in image analysis and artificial intelligence, today announced that
its first digital pathology product in a planned portfolio has been granted CE
…

Vis børsmeldingen

mark status. This means that INIFY(®) Prostate Screening is now available for
routine clinical use within the European Union.

“I am proud of the great performance by our outstanding multidisciplinary team
in reaching this company milestone. Healthcare systems around the world are
already under great stress due to heavy workloads and lack of resources - and
both patient numbers and cancer rates are only increasing. Intelligent
technology will be a vital key to addressing these challenges, with powerful
tools supporting the medical professionals in terms of efficiency and
precision,” says Fredrik Palm, CEO at ContextVision.

“We are a first mover in what I am certain will become a billion-dollar market.”

ContextVision is an independent world-wide leader within digital image
enhancement for multiple imaging modalities. With its 35-year history of
developing advanced software for digital image analysis and enhancement, it was
a natural step forward to invest in and aim for a leading position within
clinical pathology - a discipline where today’s ongoing digitalization offers
huge opportunities.

INIFY(®) Prostate Screening is a powerful AI-based software that predicts,
outlines and quantifies suspected cancerous areas in a series of prostate
biopsies. It pre-sorts slides in a worst-first order, allowing pathologists to
get right to work on the most relevant areas. While the product can be used as a
stand-alone unit, even more importantly it is designed to be seamlessly
integrated into pathology laboratories’ existing LIS (Laboratory Information
Systems) or PACS (Picture Archiving and Communication Systems).

“I can testify that it is really easy to use, saves time and helps highlight
suspicious areas for cancer.”

The predicting engine in INIFY(®) Prostate Screening is built on deep learning
algorithms, trained and adapted by ContextVision’s skilled research scientists,
resulting in proprietary high-performance algorithms with pixel-level accuracy.
Our unique, patented MasterAnnotation™ method has been used to create the
training data on which the engine is built. Here, multiplex immunofluorescent
staining is used to objectively identify and highlight cancer areas and other
structures with extreme precision, which in turn are quality assured by
certified pathologists.

“We have been involved in the development of INIFY(®) Prostate Screening and can
assure it fits laboratory needs. A prototype version of the product has been
used daily for two years in our fully digital pathology workflow here in
Catania, and I can testify that it is really easy to use, saves time and helps
highlight suspicious areas for cancer,” says Dr. Filippo Fraggetta, chief
pathologist at the Pathology Unit of Cannizzaro Hospital.

ContextVision clearly sees the need for a product that can support the
pathologist in identifying prostate cancer faster and more easily, with the
highest possible precision. INIFY(®) Prostate Screening will facilitate the
transformation of clinical pathology into a digital discipline, ultimately
offering much higher quality and standardization.

“INIFY(®) Prostate Screening will allow pathologists to focus their time on
assessing and examining prostate specimens containing suspicious cancer areas,
while minimizing time spent on benign tissue. Knowing that collaboration with
the medical profession is essential, we have worked closely with multiple
pathology labs around the world, all at the forefront of digitalization. Now,
with our first product available for clinical use within EU, we can expect
several full installations in the clinical workflow this fall. We are a first
mover in what I am certain will become a billion-dollar market,” says Palm.
“Prostate cancer is the second most common cancer in the world among men, with
2.3 million biopsy procedures carried out annually in Europe and the US alone.
With INIFY(®) Prostate Screening, we have laid a solid groundwork - which in
turn can be further adapted to address other cancer types, such as colon and
lung cancer.”

For further information, please contact ContextVision’s CEO, Fredrik Palm, at
+46 76 870 25 43 or visit www.contextvision.com.

                                  ###

About ContextVision

ContextVision is a medical technology software company specialized in image
analysis and artificial intelligence. As the global market leader within image
enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-
ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary
technology and artificial intelligence for image-based applications. Our
cutting-edge technology helps clinicians accurately interpret medical images, a
crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are
re-investing significantly in our product portfolio of decision support tools
and we are dedicated to becoming a leading resource for pathologists to
radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation
in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock
Exchange under the ticker COV.

                                  ###

This information is information that ContextVision is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, on June
29, 2020.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act

Kilde

[he67]

ContextVision podcast: How is AI revolutionizing digital pathology? •...

Spennende selskap. Verdt å høre.

[bamse]

Liten aktivitet på denne tråden. Kanskje COV fortsatt er en uoppdaget skatt ?
Markedet er enormt, COV er verdensledende og produktet er enkelt i bruk.
Kan lastes ned over nett. Får enklere innpass fordi de allerede er på plass i MR, ultralyd etc.
En “kommende Amazon” ?

[Mr.Oncoinvest]

Er inne med et lodd
Flott at de har fått fram dette fra R&D, kun basert på eksisterende kontantstrøm.

[M73102]

FA i dag (5. juli);

Kreftsatsning kan gi ny dobling

[TyrionIV]

Mulighet til å skrive en liten sammenfatning av det som står der…?

[TekBot]

Flaggemelding COV

MP Pensjon har i dag solgt 10.615 aksjer i COV og eier etter dette 4,96% av aksjene i selskapet.
…

Vis børsmeldingen

Kilde

[kreinh]

Etter antall innlegg og skribenter å dømme er det få som har tatt lodd i COV.

Kanskje kommer det noe positivt ut av dette:

ContextVision will attend ECR 2020, July 15–19.
https://www.contextvision.com/join-us-at-ecr-2020-summer-edition-july-15-19/

Dette kommer definitivt til å øke omsetningen i papiret:

Forslaget til aksjesplitt 1:10 som blir vedtatt på Ekstraordinær generalforsamling den 5 august. Med økt omsetning vil også interessen ta seg opp.

ContextVision – Invitation to Extraordinary General Meeting 2020 • ContextVision

[kreinh]

I morgen starter dette:

Join us at ECR 2020, Summer Edition, July 15–19 • ContextVision

Her kan selskapet få god reklame. Kanskje COV er noe å satse på etter en konsolidering fra ATH på 309 til dagens 251.

[kreinh]

Denne gikk meg hus forbi:

Kreftsatsning kan gi ny dobling

[rayman]

Den ligger 5-6 innlegg lenger opp i tråden…

[BareMuligheter]

Synes COV fremstår som en utrolig spennende aksje i tiden fremover. De siste dagene har aksjen blitt handlet på veldig lavt volum, og kursen har blitt styrt av ned på grunn av dette. Tipper vi får se en annen trend mot behandlingen av aksjesplitt 1:10 den 5. august med påfølgende Q2 13. august. Vil anta at markedsføringen på ECR 2020 sist uke vil føre til noe økende volum, samt at aksjesplitten vil øke omsetningen betydelig. Videre vil kommende nyheter rundt dette være kursdrivende i seg selv.

[BareMuligheter]

Stay loaded!

[Sirj4mes]

Gått mye. Men det virkelige gjennombruddet kommer nå ned Digital Pathology-løsningen deres

[kreinh]

How Medical Ultrasound May Become the Preferred Imaging Method with AI